Security record · archived quarter
CDTX
Cidara Therapeutics, Inc. · Healthcare · Biotechnology
2Tracked holders
—Δ holders
138.64KShares held
$1.66MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q4 2025 | 84 | +2 | 14.72M | $3.25B | +4 | −1 |
| Q3 2025 | 18 | +4 | 8.32M | $797.21M | +4 | — |
| Q2 2025 | 11 | +1 | 6.12M | $298.05M | +2 | −1 |
| Q1 2025 | 7 | +1 | 1.63M | $35.01M | +1 | — |
| Q4 2024 | 6 | +1 | 579.82K | $15.59M | +1 | — |
| Q3 2024 | 4 | +2 | 207.39K | $2.23M | +2 | — |
| Q2 2024 | 2 | — | 138.64K | $1.66M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 95.52K | — | $1.14M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 43.13K | — | $515,063 | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 43.13K | — | $515,063 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API